Medtech acquires Percogesic from Roche-Syntex, plans television campaign.
This article was originally published in The Tan Sheet
Executive Summary
MEDTECH ACQUIRES PERCOGESIC U.S. MARKETING RIGHTS FROM ROCHE-SYNTEX, the Jackson Hole, Wyo.- based marketer announced Jan. 2. The addition of the analgesic to the Medtech stable along with recent purchases from American Home Products is expected to boost annual sales "more than $40 mil." in 1997. Roche-Syntex acquired Percogesic, along with Aleve, from Procter & Gamble in June ("The Tan Sheet" July 1, 1996, p. 1). The pain reliever/fever reducer contains 325 mg acetaminophen and 30 mg phenyltoloxamine citrate.
You may also be interested in...
Supplement GMP Warning Letters Make Modest Debut In 2010
Finalization of a settlement between the Federal Trade Commission and Rexall Sundown regarding unsupported cellulite treatment claims for the firm's Cellasene dietary supplement hinges upon approval of two related class action settlements pending in California and Florida, according to FTC
In Brief
Combe sells most of its OTC brands
People In Brief
Perrigo promotes in pricing, planning